Neurocrine Biosciences (NBIX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- $2.85
- Estimate
- $1.96
- Surprise
- +45.4%
- Revenue (period 2026-06-30)
- $959.0M
- Score at report (before → after)
- 7.2 → 7.2/10
Revenue source: xbrl.
How the report landed
Neurocrine Biosciences (NBIX) beat the $1.96 estimate with adjusted EPS of $2.85 — a large 45.4% upside surprise. TrendMatrix's engine moved from Buy (Wait) (7.2/10) to Hold at 7.2/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates NBIX Buy (Wait) at 7.1/10.
3 of the last 4 quarters beat the estimate; this quarter's +45.4% surprise compares with a +11.6% four-quarter average. Next scheduled report: 2026-10-28.
What supports the rating
- V7 flight-to-quality bonus: +0.5 (Q=8.3 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Product: INGREZZA
- Negative momentum
- Momentum score 2.6/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $139.49
- Entry target
- $141.79
- Price target
- $187.56
- Stop
- $133.42
- Upside to target
- +34.5%
- Reward-to-risk
- 5.7:1
The stock trades at 20.8× trailing but 11.6× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 18 — a level conventionally read as oversold; trading volume is running 1.5× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-09-24 — shown for context, not personalized investment advice.
NBIX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $14.18B
- P/E (fwd)
- 11.6
- P/E (ttm)
- 20.8
- 52-week range
- $122.14–$186.12
- Off 52-week high
- 25.1%
- RSI (14)
- 18
- Volume vs avg
- 1.51×
- Score today
- 7.1/10